Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.79 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18005180 | 0.88 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL29833412 | 0.88 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18069412 | 0.88 | TGFBR1 (0.85) | TGFBR1TGFBR2 | |
| SCHEMBL18005097 | 0.85 | TGFBR1 (0.76) | TGFBR1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL18005133 | 0.83 | TGFBR1 (0.75) | TGFBR1TGFBR2 | |
| SCHEMBL29833468 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18005137 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFBR2 | |
| SCHEMBL18005264 | 0.80 | KDM4E (0.51) | TGFBR1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL3767161 | 0.76 | NR4A2 (0.61) | KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL3498049 | 0.75 | KDM4E (0.55) | TGFBR1KDM4EPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3259264-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3259264-A1 | GDF-8 INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264553-A1 | GDF-8 Inhibitors | CXCL8, MSTN, LGALS8 | TGFBR1 249/4885TGFBR2 153/4885KDM4E 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.